HOME >> BIOLOGY >> NEWS
Towards targeted lung cancer treatment

Better understanding of the mechanisms underlying cancer development has lead to the development of new anti-cancer drugs aimed at specific molecular targets. Because cancer is a heterogeneous disease, however, many of these new drugs work only in a subset of patients. They are also expensive, and they can have serious side effects. Scientists are therefore trying to find ways to predict who will benefit from a particular drug, so that they can better weigh the risks and benefits for an individual patient. In an article in the current issue of the international open-access medical journal PLoS Medicine, William Pao, Harold Varmus, and colleagues from Memorial Sloan Kettering Cancer Center in New York report results that might lead to more "targeted therapy" for lung cancer patients.

The researchers had previously shown that the epidermal growth factor (EGF) receptor, a tyrosine kinase, is often mutated in non-small-cell lung cancers, and that tumors that harbor such mutations are sensitive to two drugs called gefitinib and erlotinib. In the new study, they focused on a signaling protein called KRAS. The KRAS gene is also often mutated in lung cancers, but very few cancers have mutations in both the EGF receptor and the KRAS gene. The researchers found that those patients whose tumors had KRAS mutations had not shown an anti-tumor response when they were treated with either erlotinib or gefitinib.

These findings need to be validated by additional studies. If they are confirmed, it means that doctors should analyze tumors for mutations in the EGF receptor and KRAS before they decide whom to treat with erlotinib or gefitinib.


'"/>

Contact: Paul Ocampo
pocampo@plos.org
1-415-624-1224
Public Library of Science
24-Jan-2005


Page: 1

Related biology news :

1. Dengue and other hemorrhagic fevers: Towards a first potential treatment
2. Towards predicting late-stage radiation toxicity
3. Towards the mechanism of cell respiration
4. Towards a unified model of transcription termination
5. Towards a cheap and easy way to monitor HIV/AIDS
6. Genomic signatures identify targeted therapies for lung cancer
7. Nanocomposite labeled cancer cells can be targeted and destroyed using lasers
8. Progress toward a targeted therapy for a specific form of leukemia
9. NDDO and ESMO joined by US National Cancer Institute in conferences on targeted cancer therapies
10. Biomarkers of response to VEGF pathway-targeted therapy discovered for renal cell carcinoma
11. Light activated anticancer drug targeted to DNA using cisplatin like sub-units

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Towards targeted lung cancer treatment

(Date:11/3/2014)... Australia report that low birth weight and preterm birth ... replacements in adulthood. Findings published in the American College ... , indicate that low birth weight and pre-term babies ... to OA as adults. , According to the ... are diagnosed with clinical OA. Symptoms of OA range ...
(Date:11/2/2014)... November 2014)—In support of a bold quest to rid ... Gates Foundation today announced an award of US$156 million ... (MVI) in building new vaccines that will interrupt the ... "accelerating to zero" agenda. Such vaccines would ensure that ... called an "immunological bed net." , This approach ...
(Date:11/2/2014)... walk into a bar and bump into a biologist . ... to some late-night nerd sketch, researchers have taken this premise ... biology, namely, finding meaning in the rising oceans of genomic ... cancer mutations that genome-wide studies are publishing at a dizzying ... parse the signal from the noise (and there is no ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/21/2014)... 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... ended September 30, 2014.  Biorem,s complete 2014 third quarter financial statements ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , ... 5,281 , 6,715 , 14,476 Gross ...
(Date:11/18/2014)... LA (PRWEB) November 17, 2014 ... build-to-order, open architecture blade-based and rackmount computing infrastructure, ... Tesla® K80 dual-GPU accelerator throughout its GPU-enabled blade ... pair of the company’s latest proprietary 80-lane Gen3 ... eight discrete NVIDIA Tesla K80 dual-GPU accelerator cards ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
Cached News: